JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
JP Morgan 2022 – Beam and Mammoth hook big pharma partners
Beam signs Pfizer up for $300m up front, while Mammoth’s deal with Bayer is worth a more modest $40m.
Biopharma developments over the Christmas period
Investors nursing a fall in biotech indices now have to digest the failure of Bridgebio's acoramidis in 2021’s last important catalyst.
Another failure heaps more pressure on Novartis
Deals will come into even greater focus after the failure of ligelizumab, one of the group’s brightest pipeline hopes.
Genfit rises from the ashes of elafibranor
Ipsen hopes to draw a line under its earlier deal-making snafu with a bet on Genfit, and investors have just over a year’s wait for the proof.
Licensing deals rack up in 2021
This year has yet to see a blockbuster-style deal, but prices remain punchy nevertheless.
